Zhengyu Li

机构：Shenyang Pharmaceutical University, Xuzhou Medical College, Sichuan University, West China Second University Hospital of Sichuan University, Central State Medical Academy · ORCID：0000-0003-1995-9812

发表论文 80 篇 · 总被引 838 次 · h-index 16

代表论文

• Organoids in ovarian cancer: a platform for disease modeling, precision medicine, and drug assessment (2024 · Journal of Cancer Research and Clinical Oncology · 被引 16)
• TAB: Unified Benchmarking of Time Series Anomaly Detection Methods (2025 · Proceedings of the VLDB Endowment · 被引 14)
• Efficacy and safety of neoadjuvant chemotherapy containing anti-angiogenic drugs, immunotherapy, or PARP inhibitors for ovarian cancer (2023 · Critical Reviews in Oncology/Hematology · 被引 11)
• Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer (2023 · Frontiers in Pharmacology · 被引 10)
• Enhancement of HPV therapeutic peptide-based vaccine efficacy through combination therapies and improved delivery strategies: A review (2024 · Human Vaccines & Immunotherapeutics · 被引 6)
• The Clinical Effectiveness of Single-Dose Human Papillomavirus Vaccination (2024 · Vaccines · 被引 5)